Spec market sell off is providing a compelling opportunity back in BOT with a product which works and management who aren't strangers to the FDA process or delivering massive shareholder returns.
Initially I bought BOT 12 months ago and held it all the way into the teens. It will follow a similar trajectory as we edge closer to full recruitment of Phase 2 trial results.
Near term upside from Permetrex and the new potential applications in BTX 1308: psoriasis BTX 1801: antimicrobial will re-rate us in the meantime.
Ann: Botanix Presents at Fall Clinical Dermatology Conference, page-66
-
- There are more pages in this discussion • 120 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
36.0¢ |
Change
-0.020(5.26%) |
Mkt cap ! $651.6M | |||
| Open | High | Low | Value | Volume |
| 37.0¢ | 37.5¢ | 36.0¢ | $1.832M | 5.001M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 30 | 1023317 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 36.5¢ | 3589 | 1 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| BOT (ASX) Chart |